Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 STOPP criteria that were not assessed in the LiLACS NZ study

From: Quality of prescribing predicts hospitalisation in octogenarians: life and living in advanced age: a cohort study in New Zealand (LiLACS NZ)

CriteriaReason for non-assessment
Cardiovascular System
 Aspirin with a past history of peptic ulcer disease without histamine H2 receptor antagonist or Proton Pump InhibitorPeptic Ulcer Disease was recorded only if an active condition i.e. history was not investigated
 Warfarin for first, uncomplicated deep venous thrombosis for longer than 6 monthsReason for treatment with warfarin was not documented
 Warfarin for first uncomplicated pulmonary embolus for longer than 12 months durationReason for treatment with warfarin was not documented
 Aspirin, clopidogrel, dipyridamole or warfarin with concurrent bleeding disorderPresence of bleeding disorder was not recorded
Central Nervous System
 TCA’s with prostatism or prior history of urinary retentionHistory of urinary retention
 Long-term (i.e. >  1 month) neuroleptics as long-term hypnoticsIndication for neuroleptics was not documented
 Selective serotonin re-uptake inhibitors (SSRI’s) with a history of clinically significant hyponatraemiaHyponatraemia was noted if present, but not if patients had a history of it
Gastro-intestinal System
 Diphenoxylate, loperamide or codeine phosphate for treatment of diarrhoea of unknown causeDiarrhoea as an indication was not recorded
 Diphenoxylate, loperamide or codeine phosphate for treatment of severe infective gastroenteritisGastroenteritis as an indication was not recorded
Musculoskeletal System
 Non-steroidal anti-inflammatory drug (NSAID) with history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent histamine H2 receptor antagonist, PPI or misoprostolPeptic Ulcer Disease was recorded only if an active condition i.e. history was not investigated
Urogenital System
 Alpha-blockers in males with frequent incontinence i.e. one or more episodes of incontinence dailyPresence of incontinence was not recorded
 Alpha-blockers with long-term urinary catheter in situ i.e. more than 2 monthsPresence of a catheter was not recorded